Chapters

Transcript

Video

What novel strategies—in particular, CRF receptor antagonism with crinecerfont—might be considered address the “therapeutic burden” associated with glucocorticoid therapy in CAH?

What novel strategies—in particular, CRF receptor antagonism with crinecerfont—might be considered address the “therapeutic burden” associated with glucocorticoid therapy in CAH?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Perrin White, MD

Perrin White, MD

Chief, Division of Pediatric Endocrinology
Audre Newman Rapoport Distinguished Chair in Pediatric Endocrinology
UT Southwestern Medical Center
Dallas, TX